Donor screening for human T-cell lymphotrophic virus 1/2: Changing paradigms for changing testing capacity

D. R. Kaul, S. Taranto, C. Alexander, S. Covington, M. Marvin, M. Nowicki, J. Orlowski, C. Pancoska, T. L. Pruett, M. G. Ison

Research output: Contribution to journalShort survey

24 Scopus citations

Abstract

Organ Procurement and Transplant Network (OPTN) policy currently requires the testing of all potential organ donors for human T-cell lymphotrophic virus (HTLV)-1/2. Most Organ Procurement Organizations (OPO) use the Abbott HTLV-I/HTLV-II Enzyme Immunoassay (EIA). This assay will no longer be manufactured after December 31, 2009; the only commercially available FDA-licensed assay will be the Abbott PRISM HTLV-I/II assay which poses many challenges to OPO use for organ donor screening. As a result, screening donors for HTLV-1/2 in a timely manner pretransplant after December 31, 2009 will be challenging. The true incidence of HTLV-1 in United States (U.S.) organ donors is not well described but appears to be low (∼0.03-0.5%). HTLV-1 is associated with malignancy and neurological disease; HTLV-2 has not been convincingly associated with disease in humans. Donors that are HTLV-1/2 seropositive are infrequently used despite most results being either false positive or resulting from HTLV-2 infection. There is urgent need to encourage the development of assays, instruments and platforms optimized for organ donors that can be used to screen for transmissible disease in donors; these must have appropriate sensitivity and specificity to identify all infections while minimizing organ loss through false positive testing.

Original languageEnglish (US)
Pages (from-to)207-213
Number of pages7
JournalAmerican Journal of Transplantation
Volume10
Issue number2
DOIs
StatePublished - Feb 1 2010

Keywords

  • Donor evaluation
  • Donor-to-host transmission
  • Infectious diseases
  • Viral infection

ASJC Scopus subject areas

  • Immunology and Allergy
  • Transplantation
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Donor screening for human T-cell lymphotrophic virus 1/2: Changing paradigms for changing testing capacity'. Together they form a unique fingerprint.

  • Cite this

    Kaul, D. R., Taranto, S., Alexander, C., Covington, S., Marvin, M., Nowicki, M., Orlowski, J., Pancoska, C., Pruett, T. L., & Ison, M. G. (2010). Donor screening for human T-cell lymphotrophic virus 1/2: Changing paradigms for changing testing capacity. American Journal of Transplantation, 10(2), 207-213. https://doi.org/10.1111/j.1600-6143.2009.02867.x